Dr. Róisín McManus’ Post

👇 Check out this new review paper!

Fibrin drives thromboinflammation and neuropathology in COVID-19 Study: fibrin-targeting immunotherapy may represent a therapeutic intervention for patients with acute #COVID19 and #longCOVID https://lnkd.in/gwBK9kyC

CAR-T #celltherapy is revolutionizing the treatment of #autoimmunediseases, building on its success in tackling B cell malignancies. Recent advances in CD19-based and BCMA-based #CARTtherapies show promising results for diseases such as systemic #lupus erythematosus, idiopathic inflammatory myopathy, systemic sclerosis, and #multiplesclerosis. This groundbreaking approach, which targets and depletes autoreactive B cells, aims to reset the immune system and restore normal function. While these are innovative advancements, patient selection, safety, efficacy, and ongoing medical management are critical for improving outcomes. As the field evolves, these aspects will continue to be refined to maximize the potential of CAR-T cell therapy in autoimmune diseases. Find the full article in the comments below!

💜 The month of June is Alzheimer's and Brain Awareness Month   🧠 Did you know? #Alzheimersdisease is the most common cause of #dementia, affecting memory, thinking, and behaviour. In order to raise awareness and show support for those affected, it is essential to educate ourselves and others about this condition.   At Galimedix Therapeutics, Inc., we are working to improve the lives of millions of patients by developing game-changing drugs to treat major neurodegenerative diseases, such as Alzheimer's.   Visit https://lnkd.in/gGgBQhY for more infos on the fight against this devastating disease.   #AlzheimersAwareness #BrainHealth #ENDALZ

This ALS Awareness Month, we at Zydus are accelerating our efforts to discover & develop novel candidates for treating Amyotrophic Lateral Sclerosis (ALS), a fatal neurodegenerative disease. Today we announced the completion of Enrolment for Phase II clinical trial of Usnoflast, a novel oral NLRP3 inflammasome inhibitor under clinical development in patients with Amyotrophic Lateral Sclerosis (ALS).   ALS patients experience neuroinflammation and rapid neurodegeneration leading to steady loss of the ability to move, speak, eat and eventually breathe. ALS results in the loss of motor neurons in the brain and spinal cord which controls voluntary muscle movement. #Zydus #ZydusResearchCentre #YouInspireUs #alsawarenessmonth #NewDrugDiscovery #DrugDevelopment #ZydusUniverse #ALS

Discover the innovative potential of targeting lymphatic function in cardiovascular-kidney-metabolic (CKM) syndrome! The article explores how enhancing lymphatic function could revolutionize treatment by addressing multiple pathologies simultaneously. Learn more about promising therapeutic targets that might shape the future of CKM therapy. Read the full article here 🔗 https://bit.ly/3VT0LwT #CaReMeO2024 #diabetes #cardiovasculardisease #renaldisease #primarycarephysicians

Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease PR Newswire - Press Releases US - English Posted 02-Jul-2024 at 1:35 pm EST Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study and reduced participants' risk of progressing to the next clinical stage of disease by up to 39% Kisunla is the first and only amyloid plaque-targeting therapy that used a limited-duration treatment regimen based on amyloid plaque removal; nearly half of study participants completed their course of treatment with Kisunla in 12 months Once-monthly infusions of 30 minutes reduced amyloid plaques on average by 84% compared to the start of the study

New treatment options that directly address the underlying condition are needed for autoimmune diseases. As co-chair of Bristol Myers Squibb’s recently formed ACTioN, I am thrilled to connect with this group of leaders in #CARTcelltheray and #immunology at #EULAR2024 to discuss our collective goal of discovering how cell therapy can transform the treatment landscape. Visit our ACTioN page on BMS.com to learn more about the potential of cell therapy in immunology: https://rb.gy/92nksr #BMS_Employee

Recent advancements in cancer supportive care research are unveiling exciting prospects for enhancing patient well-being during treatment. Studies highlight the therapeutic potential of high-dose oral vitamin D in managing skin toxicities linked to cancer treatment. Additionally, the benefits of incorporating yoga into care plans are being recognized for their effectiveness in reducing cancer-related fatigue and symptoms of depression. These developments hold promise for improving the quality of life for cancer patients undergoing treatment. #CancerResearch #SupportiveCare #PatientWellBeing www.alkaohri.org

Acetylcholinesterase inhibitors are frequently used in the treatment of Alzheimer disease due to their anti-inflammatory effects. But what is the potential of this class of medications to also impact the risk of age-related macular degeneration in this patient population? Joseph Magagnoli, MS, discusses the results of his team's study, as well as the relationship between AD and AMD and remaining gaps in the literature, in this Q&A. Click here to read the full article: https://okt.to/O4f5HV